Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP).
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Levofloxacin (Primary)
- Indications Bacterial infections; Prostatitis
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jul 2009 Planned patient number (120) added as reported by ClinicalTrials.gov.
- 12 Sep 2006 New trial record.